Upcoming FDA decision · October 29, 2026
tildrakizumab PDUFA date: FDA decision expected October 29, 2026
36 days to goMERCK (MRK) →
The FDA is expected to decide on tildrakizumab from MERCK in Psoriasis by the PDUFA target action date of October 29, 2026. For Adults with Active Psoriatic Arthritis If the sBLA is approved. sbla filing. AI-extracted from news: Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUM
A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.
October 29
Target action date
Phase 2
Stage
Detected
Date confidence
—
FDA designations